Goldvaser Hadar, Purim Ofer, Kundel Yulia, Shepshelovich Daniel, Shochat Tzippy, Shemesh-Bar Lital, Sulkes Aaron, Brenner Baruch
Davidoff Cancer Center, Rabin Medical Center, Institute of Oncology, Beilinson Hospital, 39 Jabotinski St., Petach Tikva, 49100, Israel.
Sackler Faculty of Medicine, Tel Aviv University, P.O Box 39040, Tel Aviv, Israel.
Int J Clin Oncol. 2016 Aug;21(4):684-695. doi: 10.1007/s10147-015-0935-z. Epub 2016 Jan 28.
The incidence of colorectal cancer in young patients is increasing. It remains unclear if the disease has unique features in this age group.
This was a single-center, retrospective cohort study which included patients diagnosed with colorectal cancer at age ≤40 years in 1997-2013 matched 1:2 by year of diagnosis with consecutive colorectal cancer patients diagnosed at age >50 years during the same period. Patients aged 41-50 years were not included in the study, to accentuate potential age-related differences. Clinicopathological characteristics, treatment, and outcome were compared between groups.
The cohort included 330 patients, followed for a median time of 65.9 months (range 4.7-211). Several significant differences were noted. The younger group had a different ethnic composition. They had higher rates of family history of colorectal cancer (p = 0.003), hereditary colorectal cancer syndromes (p < 0.0001), and inflammatory bowel disease (p = 0.007), and a lower rate of polyps (p < 0.0001). They were more likely to present with stage III or IV disease (p = 0.001), angiolymphatic invasion, signet cell ring adenocarcinoma, and rectal tumors (p = 0.02). Younger patients more frequently received treatment. Young patients had a worse estimated 5-year disease-free survival rate (57.6 vs. 70 %, p = 0.039), but this did not retain significance when analyzed by stage (p = 0.092). Estimated 5-year overall survival rates were 59.1 and 62.1 % in the younger and the control group, respectively (p = 0.565).
Colorectal cancer among young patients may constitute a distinct clinical entity. Further research is needed to validate our findings and define the optimal approach in this population.
年轻患者中结直肠癌的发病率正在上升。目前尚不清楚该疾病在这个年龄组中是否具有独特特征。
这是一项单中心回顾性队列研究,纳入了1997年至2013年期间诊断为结直肠癌且年龄≤40岁的患者,按诊断年份以1:2的比例与同期诊断为结直肠癌且年龄>50岁的连续患者进行匹配。41至50岁的患者未纳入本研究,以突出潜在的年龄相关差异。比较了两组之间的临床病理特征、治疗情况和结局。
该队列包括330例患者,中位随访时间为65.9个月(范围4.7至211个月)。发现了几个显著差异。较年轻组有不同的种族构成。他们有更高的结直肠癌家族史发生率(p = 0.003)、遗传性结直肠癌综合征发生率(p < 0.0001)和炎症性肠病发生率(p = 0.007),而息肉发生率较低(p < 0.0001)。他们更有可能表现为III期或IV期疾病(p = 0.001)、血管淋巴管浸润、印戒细胞腺癌和直肠肿瘤(p = 0.02)。较年轻的患者更频繁地接受治疗。年轻患者的估计5年无病生存率较差(57.6%对70%,p = 0.039),但按分期分析时这一差异无统计学意义(p = 0.092)。较年轻组和对照组的估计5年总生存率分别为59.1%和62.1%(p = 0.565)。
年轻患者中的结直肠癌可能构成一个独特的临床实体。需要进一步研究来验证我们的发现并确定该人群的最佳治疗方法。